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A B S T R A C T
The aim of the study was to investigate the influence of radioiodine (RAI) therapy on pregnancies and the health sta-
tus of children born to mothers who had received therapeutic doses of I-131 for differentiated thyroid carcinoma (DTC).
Gestational histories of 76 women treated for DTC from 1971–2005 were retrospectively analyzed. The outcome of 49
pregnancies after RAI was: 35 children (72%), 5 (10%) miscarriages and 9 (18%) induced abortions. RAI did not ad-
versely affect the rate of successful delivery and live birth demographics. Congenital malformation and first year mortal-
ity were not observed. The children's ages range from 1 month to 29 years (X±SD=8.0±8.4). A higher therapeutic dose
(100 mCi) did not significantly alter the pregnancy outcome. There is no reason to discourage females treated with
I-131 from becoming pregnant. Patients should avoid pregnancy after RAI administration for 1 year.
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Introduction
Radioactive iodine I-131 (RAI) has been used for de-
cades in the diagnosis and treatment of well differentiated
thyroid carcinoma (DTC). It is an effective treatment of
DTC, both in preventing relapses and treating metastas-
es1–7. Following total thyroidectomy, patients are adminis-
tered a diagnostic dose of 37–185 MBq I-131 and subse-
quently a therapeutic dose, varying from 1.85 to 3.70 GBq
I-131 for the ablation of the thyroid remnant or evenmore
for the therapy of the metastatic disease, if necessary.
The thyroid gland is an uncommon site of cancer, ac-
counting for 0.6% and 1.6% of cancers among men and
women, respectively8,9. However, if the age distribution is
analyzed, a considerable number of patients in their
younger age are found. The peak age for developing pap-
illary carcinoma is about 30 years of age, for follicular
carcinoma 45 years of age and both types are about three
times more frequent in women. Of all 1231 patients
treated for well differentiated thyroid carcinoma from
1971–2005 at the Department of Oncology and Nuclear
Medicine, University Hospital Sestre Milosrdnice in Zag-
reb, 956 (78%) were woman, of which 180 (19%) were
younger than 35 years.
A large number of young female patients may be con-
sidered cured after thyroidectomy and radioiodine ther-
apy and their desire to have a child is therefore normal.
However, it is well known that radiation exposure in-
duces genetic mutation, which can result in genetic ab-
normalities in the newborns. Therefore, beside positive
effects of such therapy, great interest has been shown in
the research of possible mutagenic effect on germ cells,
which could result in adverse outcome of pregnancy
(spontaneous abortions, congenital abnormalities, malig-
nancies in offspring). During pregnancy, well-defined
changes in thyroid hormone physiology reflect an in-
creased demand for thyroid hormone production (in one-
third of patients on L-thyroxin therapy a dosage increase
is required), which can also affect the pregnancy out-
come10–12. It is difficult to assess the effect of RAI therapy
due to a small number of patients (thyroid carcinoma is
not a frequent disease) and their restrictive age. Also, the
patients appear to be less willing to have children, partic-
ularly if they were already parents, because of their pri-
mary disease. Several studies addressing this problem
did not find statistically significant associations between
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previous RAI exposure and unfavorable pregnancy out-
come except for miscarriages13–21. In our previously pub-
lished data, a slight increase of miscarriages was also
observed19. The largest reported series by Schlumberger
et al.21 revealed that the miscarriage rate increased from
11% to 20% after surgery for DTC, irrespective of the use
of RAI. More miscarriages were observed among the
women treated with RAI in the year immediately preced-
ing conception (40%), but there was no other unfavorable
pregnancy outcome. However, it is hard to estimate real
radiation risk as clinical data are still insufficient to as-
sess the low level of RAI risk, compared to other influ-
ences which have an impact on pregnancy outcome22.
The aim of our study was to further evaluate the in-
fluence of radioiodine therapy on pregnancies and the
health status of children born to mothers who had re-
ceived therapeutic doses of I-131 for DTC, at the Depart-
ment of Oncology and Nuclear Medicine, University Hos-
pital Sestre Milosrdnice.
Patients and Methods
A group of 76 female patients, who were less than 35
years at the time when they were treated for DTC, were
evaluated. They were all referred to the Department of
Oncology and Nuclear Medicine, University Hospital
Sestre Milosrdnice in the period from 1971 to 2005 and
received regular follow-up. During routine check-ups be-
tween January 2003 and April 2005 pregnancy history,
outcome and physical and intellectual condition of their
children were assessed.
According to histological type of cancer, 71 patients
(93%) had papillary and 5 patients (7%) follicular carci-
noma. All patients were treated according to the stan-
dard protocol. After total thyroidectomy an ablation dose
of 1.85–3.70 giga Becquerel (GBq) I-131 (50–100 mili
Cürie mCi) was administered for the ablation of thyroid
remnants. Radioiodine administration was repeated in 3,
6 or 12-month intervals until significant uptake in thy-
roid bed had completely disappeared. One patient had
lung and bone metastases at presentation and one devel-
oped lung metastases during follow-up period. They were
treated with additional RAI doses and RAI treatment re-
sulted in complete remission in these two patients. The
average dose for metastatic disease at our department
was 5.55 GBq (150 mCi). The numbers of I-131 adminis-
trations were the following: 41 patients received a single
dose, 28 patients received two, 5 patients received three,
one patient received four and one six doses. Total doses
varied from 1.85 to 28.86 GBq I-131 (50–780 mCi), X±
SD=5.72±3.87 GBq, median 3.70.
The age of patients at first radioiodine administration
for therapeutical purposes ranged between 12 and 35
years (X±SD=25.9±5.6 years, median 26 years). All pa-
tients were recommended to avoid pregnancy after each
I-131 administration for 12 months.
The patients were followed up according to the follow-
ing protocol: whole body scintigraphy was performed 72
hours after the administration of 37–185 mega Becquerel
(MBq) I-131 (1–5 mCi). Thyroxin substitution therapy
was discontinued four weeks prior to whole body scinti-
graphy and TSH level confirmed to be 30 IU. Thyroglob-
ulin level was measured and ultrasound of the neck per-
formed, along with routine clinical examination and chest
X-ray if indicated.
After the therapy, all patients were given thyroxin at
doses capable of suppressing thyroid stimulating hor-
mone (TSH). Serum TSH level was measured regularly,
while suppression doses were adjusted individually ac-
cording to the obtained results. This was done in order to
obtain optimal suppression effect with the smallest
amount of thyroxin and thus avoid possible iatrogenic
hyperthyroidism. Later during the follow-up period, in
the patients who were free of disease thyroxin dose was
decreased until normal TSH values were obtained. In the
patients who were planning pregnancy, the thyroxin dose
was also decreased and serum TSH levels titrated to
reach the normal range. During the first trimester of
pregnancy, thyroxin dose was increased and TSH levels
carefully monitored for dosage adjustment since there is
increased demand for thyroid hormone production dur-
ing that period. Separation of thyroxin ingestion by at
least four hours from iron and calcium supplements was
recommended.
Clinical data on pregnancies were obtained during a
routine check-up of patients, including pregnancy details
and outcome, live birth demographic data and the physi-
cal and intellectual condition of these children (the latest
was assessed subjectively by their mothers by compari-
son with other siblings and peer group).
Statistical analysis
Numerical data were presented as mean, standard de-
viation, or median with range. Qualitative data were de-
scribed by frequencies and percentages. Mann-Whitney
test was used to compare numerical data of two inde-
pendent groups, while qualitative data were compared by
two-sided Fisher’s exact test. For statistical analysis, the
SAS System for Windows, Release 8.02, TS Level 02M0
(SAS Institute Inc., Cary, NC, USA) was used.
Results
The mean follow-up of these 76 patients was 9.4
years, SD=7.0, median 7.7, range 1–32 years.
Seventy-six women evaluated gave birth to a total of
91 children, of which 56 were born before any treatment
for DTC.
After surgery for thyroid carcinoma and administra-
tion of therapeutical activities of RAI, 45 women (58%)
had no wish to become pregnant and of the remaining 31
women who declared that they were not avoiding preg-
nancies, 24 women (32%) gave birth, 2 (3%) had 1 mis-
carriage each and 5 (7%) did not conceive (Figure 1).
The outcome of 49 total pregnancies that occurred af-
ter radioiodine therapy was: 35 children (72%) were
born, 5 (10%) miscarriages were observed and 9 (18%)
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pregnancies ended by induced abortion. Three of these
nine induced abortions were performed because they oc-
curred during the period of 6 months after the RAI ther-
apy, four pregnancies were terminated to prevent a feared
negative outcome and reasons for other two abortions
were not specified. After exclusion of pregnancies termi-
nated by induced abortion, 5 miscarriages (12.5%) were
observed in the 40 remaining pregnancies. Twenty-four
women gave birth to a total of 35 children (22 males and
13 females). Nulliparous women easily decided to be-
come, which is evident from data that 16 of these women
gave birth to total of 27 children. Eight women who pre-
viously had children gave birth to one more each.
Median activity of I-131 prior to pregnancy was 3.7
GBq (100 mCi), range 2.96–28.86 GBq (80–780 mCi). The
largest single dose administered was 5.55 GBq (150 mCi).
Mean number of applications was 1.6 (SD=1.2, range
1–6). Patient's ages at the time of pregnancy ranged 18 to
40 years, X±SD=28.9±5.1, median 30.0 years. The in-
terval between the last administration of I-131 and con-
ception ranged 0.4 to 19 years, X±SD=6.0±5.1, median
4.0 years.
We also studied whether a higher total RAI dose had
any association with adverse pregnancy outcome. Preg-
nancies occurred after the RAI therapies were classified
according to I-131 dose before each pregnancy into two
groups: Group A 	100 mCi and Group B 100 mCi (Fig-
ure 2).
The clinical characteristics of patients, pregnancy out-
comes and children in each group are presented in Table
1 and Table 2.
There was no difference between the groups for the
age when DTC was diagnosed (p=0.643), follow-up pe-
riod (p=0.227), the maternal age at pregnancy (p=0.953)
or the interval between RAI and pregnancy (p=0.267).
Stillbirths, congenital abnormalities or first year neo-
natal mortality were not recorded. We did not find any
difference in the adverse effects on outcome between low
and high total I-131 dose groups. The proportion of live
births was similar and after excluding pregnancies ended
by elective abortion, the incidence of miscarriage was not
different between the RAI groups (13% vs. 11%, p=
0.999). Also, no difference was noted in the gender distri-
bution (p=0.680), or children’s birth weight (p=0.723)
between the groups with different total I-131 dose ad-
ministration. To the present, the children's ages’ range
from 1 month to 29 years, X±SD=7.8±8.1, median 6.0
years. All children had normal growth and have not been
afflicted with severe disease.
Discussion
The diagnostic and therapeutic use of I-131 for the
evaluation and management of thyroid remnants and re-
gional and distant metastases of differentiated thyroid
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Fig. 1. Distribution of patients according to the intention to have
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Fig. 2. Outcome of pregnancies as a function of total I-131
administration.
TABLE 1
CLINICAL CHARACTERISTICS OF PATIENTS ACCORDING TO PRECONCEPTION I-131 ADMINISTRATION
Characteristics
Group A (	100 mCi) Group B (100 mCi)
p
Median Range Median Range
I-131 Dose (mCi) 91 30 200 672 <0.001*
Fractions (n) 1 1 2 5 <0.001*
Maternal age at DTC
 diagnosis (y) 23 16 26 20 0.643
Interval before pregnancy (y) 4 17 6.5 16 0.267
Maternal age at pregnancy (y) 29 22 30 10 0.953
Patient’s follow-up (y) 11.6 30.5 9 18 0.227
Children’s birth weight (kg) 3.4 1.6 3.3 0.7 0.723
Age of child at last follow-up (y) 8 28.9 1.5 4.8 0.006*
 p0.05, Group A	100 mCi I-131, Group B100 mCi I-131, 
DTC-Differentiated Thyroid Carcinoma
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carcinoma (DTC) have been routine for decades. Long-
term studies1,5,23 reported that I-131 ablation of residual
thyroid tissue after surgery decreased the risk of recur-
rence and cancer-specific mortality rates were signifi-
cantly lower than in those who did not undergo remnant
ablation. Since all diagnostic and therapeutic modalities
should be assessed carefully for the relative benefits and
hazards, the purpose of this study was to evaluate, in a
clinical setting, the impact of I-131 therapy on pregnancy
outcomes and the health status of their children born.
Knowledge that radiation is mutagenic and may af-
fect gonads (thereby resulting in genetic damage to off-
spring) has raised concern regarding the use of radio-
iodine in patients during their reproductive years. Vir-
tually every patient treated with any dose of I-131 is ex-
posed to some potential risk. The potential hazards that
have the greatest impacts on the decision to utilize this
modality are the induction of second tumors18,24,25 and
genetic and chromosomal damage16–21,26–30. Also, a large
individual variation in the reaction to RAI exposure was
observed due to differences in each individual’s features
and environment.
Genetic risk of ionizing radiation in humans has been
estimated in the offspring of survivors of the atomic
bomb explosion31,32, in populations living in areas of high
background radiation levels33 and in the descendants of
persons exposed to radiation either on the job34, or through
diagnostic and therapeutic procedures35. Studies on sur-
vivors of the atomic bomb explosion in Japan31,32 and of
childhood and adolescent cancer survivors who had re-
ceived radiation to the abdomen or pelvis36 have failed to
provide any clear evidence of increased germ cell muta-
tion subsequent to exposure, but some studies have sug-
gested an increased risk of congenital abnormalities33
and leukemia37 in children born to occupationally ex-
posed men.
It has been estimated that the radiation dose deliv-
ered to the ovary is approximately 0.14 cGy after admin-
istration of 37 MBq (1 mCi) of radioiodine38, which corre-
lates well with in vivo measured doses39. Since the rate of
congenital anomalies due to RAI exposure is low com-
pared to the other influences that have an impact on
pregnancies outcome, it is hard to estimate the risk. The
rate of spontaneous birth anomalies is 800 per 100.000
pregnancies and if all 100.000 women received 370 MBq
(10 mCi) I-131 before they became pregnant, the rate of
congenital anomalies would increase to 803 (only 3 new
congenital anomalies on 100.000 women exposed with 10
mCi I-131)22. In addition, there are genetic diseases that
are either easily recognized but uncommon, or more fre-
quent but difficult to detect.
So far, studies about the impact of I-131 therapy on
pregnancies included small number of patients and failed
to reveal any significant I-131 related effect13–21,28. Even
in the largest study reported21, with data on 2113 preg-
nancies evaluated, 272 pregnancies presented referred to
the period after the surgery for thyroid cancer and only
206 to the period after the RAI administration.
Our data show that all children born to mothers who
had received therapeutic activities of I-131 for DTC had
birth weight similar to the birth weight of healthy new-
borns from the Zagreb County, Croatia40 and were in
good health. The only untoward outcome of pregnancy
was 5 (12.5%) miscarriages. One miscarriage occurred
when the patient was off the substitution therapy with
thyroxin and in two others, miscarriages occurred within
6 month following thyroidectomy and radioiodine ther-
apy (subsequently these women had healthy children).
Therefore, the contribution of other factors, as an inade-
quate control of the thyroid hormonal status, cannot be
excluded (both hyperthyroidism and hypothyroidism
have significant effects on estrogen metabolism, fertility
and pregnancy outcome). Many factors capable of inter-
fering with the hypothalamic-pituitary-thyroid axis may
induce changes in TSH level and affect the pregnancy, so
thyroid hormonal status should be carefully followed-up.
In the general population, the incidence of miscar-
riages in clinical recognized pregnancies is about 10%41,
but in prospective studies, when healthy women at-
tempting to conceive were under medical supervision,
the incidence of miscarriages was significantly higher. In
the study of 221 healthy women attempting to conceive,
early pregnancy loss (1 to 91 days after the implantation)
was 31%42. In similar studies the incidence ranges from
18%43 up to even 63%44. In the general population a great
deal of early pregnancy loss remains clinically unrecog-
nized. Patients with a diagnosis of DTC are under more
strict medical control because of their primary disease
and their pregnancies are usually planned and more
carefully supervised.
In our group of patients, worst pregnancy outcome
was not associated with higher total RAI therapy dose.
Although our data do not establish that no risk exists,
they indicate low level of RAI ablation risk and empha-
size the importance of individual differences due to non-
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TABLE 2
CLINICAL CHARACTERISTICS OF PATIENTS ACCORDING
TO PRECONCEPTION I-131 ADMINISTRATION
Characteristics
Group A
(	100 mCi)
Group B
(100 mCi) p
N % N %
Pregnancies after I-131 36 100 13 100
Pregnancy outcome 0.999
Live births 27 75 8 61
Miscarriages 4 11 1 8
Induced abortions 5 14 4 31
(Therapeutic) 0 3
(Social/psychological) 3 1
(Unspecified) 2 0
Live birth – gender 0.680
Female 11 41 2 25
Male 16 59 6 75
Group A	100 mCi I-131, Group B100 mCi I-131
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uniform distribution of internally deposited radionucli-
des and different level of gene activity and chromosome
repair in each patient. However, in the recently pub-
lished Erselcan study29 the connection between the dose
and the chromosomal damage has been established. The
authors evaluated acute and late chromosomal damage
in the peripheral lymphocytes of 15 patients who re-
ceived various doses of I-131. Acute and late effects were
defined using the »damage ratio« (acute effect) and the
»recovery ratio« (late effect), based on the basal, acute
(3rd day) and late (6 months) data in patients treated for
thyrotoxicosis or DTC. The »damage ratio« was not re-
lated to the dose administered, but a negative correlation
was found between the I-131 dose and the »recovery ra-
tio«. Results also suggested that part of the damaged
lymphocytes disappear from the circulation in a dose de-
pendent manner following I-131 treatment. These re-
sults, together with other studies indicate dose-effect re-
lationship at the chromosomal level45,46.
Although, previous studies do not indicate any in-
crease in the untoward pregnancy outcome except for
miscarriages13–21,28, there is a need for further studies to
assess biological effects and clinical impact of RAI therapy
in patients receiving different therapeutic doses of I-131.
Conclusion
On the basis of the present data and data from previous
studies on this subject, there is no reason to discourage
patients treated with radioiodine therapy from becoming
pregnant. The incidence of spontaneous abortions, still-
births, congenital abnormalities or malignancies in the
offspring was not increased. Also, higher therapeutic
doses did not affect the outcome. However, patients should
be advised to avoid pregnancy after I-131 administration
for 1 year. Thyroid hormonal status should be evaluated
prior to pregnancy and during pregnancy thyroxin dose
carefully adjusted.
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TRUDNO]E U @ENA LIJE^ENIH RADIOAKTIVNIM JODOM RADI DIFERENCIRANOG
KARCINOMA [TITNJA^E
S A @ E T A K
Cilj studije bio je utvrditi utjecaj radioaktivnog joda (RAI) na trudno}e, kao i na zdravlje djece bolesnica koje su
primale terapijske doze I-131 radi diferenciranog karcinoma {titnja~e (DTC). Trudno}e u 76 bolesnica lije~enih radi
DTC-a u periodu od 1971.–2005. g. su retrospektivno analizirane. Ishod 49 trudno}a koje su uslijedile nakon terapije
RAI bio je: 35 djece (72%), 5 spontanih poba~aja (10%) i 9 arteficijalnih poba~aja (18%). Terapija radioaktivnim jodom
nije negativno utjecala na stopu uspje{nih poroda, niti na demografske osobine novoro|en~adi. Kongenitalne malfor-
macije i mortalitet u prvoj godini `ivota nisu registrirani. Srednja dob djece bila je 8 godina (raspon 1 mjesec do 29
godina, SD=8.4). U bolesnica koje su primile ve}e terapijske doze radioaktivnog joda (100 mCi) nije registriran lo{iji
ishod. Bolesnicama lije~enim radioaktivnim jodom radi diferenciranog karcinoma {titnja~e nije potrebno preporu~ivati
izbjegavanje trudno}e. Preporu~a se izbjegavati trudno}u u godini neposredno nakon primanja terapije I-131.
A. Balenovi} et al.: Pregnancy Outcome after I-131 Treatment, Coll. Antropol. 30 (2006) 4: 743–748
748
U:\coll-antropolo\coll-antro-4-2006\BALENOVIC.vp
19. prosinac 2006 15:38:59
Color profile: Disabled
Composite  150 lpi at 45 degrees
